|
1
|
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.
|
JAMA
|
1991
|
6.05
|
|
2
|
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
|
Circulation
|
2001
|
3.96
|
|
3
|
Blood-pressure reduction and cardiovascular risk in HOPE study.
|
Lancet
|
2002
|
3.77
|
|
4
|
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
|
Circulation
|
1994
|
2.84
|
|
5
|
Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.
|
Circulation
|
1999
|
2.79
|
|
6
|
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.
|
Eur Heart J
|
2000
|
1.88
|
|
7
|
Surrogate endpoints in clinical trials: cardiovascular diseases.
|
Stat Med
|
1989
|
1.68
|
|
8
|
Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers.
|
Am J Cardiol
|
1990
|
1.39
|
|
9
|
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
|
Can J Cardiol
|
1997
|
1.33
|
|
10
|
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Control Clin Trials
|
2001
|
1.12
|
|
11
|
Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.
|
Eur J Prev Cardiol
|
2011
|
1.00
|
|
12
|
Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators.
|
Am Heart J
|
1996
|
0.92
|
|
13
|
Venous thromboembolism in association with features of the metabolic syndrome.
|
QJM
|
2007
|
0.86
|
|
14
|
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP).
|
Am J Hypertens
|
1995
|
0.85
|
|
15
|
Community volunteers as recruitment staff in a clinical trial: the systolic hypertension in the elderly program (SHEP) experience.
|
Control Clin Trials
|
1996
|
0.83
|
|
16
|
Analysis strategies for serial multivariate ultrasonographic data that are incomplete.
|
Stat Med
|
1992
|
0.81
|
|
17
|
Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.
|
Can J Cardiol
|
2006
|
0.81
|
|
18
|
Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
|
Circulation
|
1999
|
0.76
|
|
19
|
Prospective meta-analysis: ahoy! A clinical trial?
|
J Am Geriatr Soc
|
1995
|
0.75
|
|
20
|
Neurohumoral variability in left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction.
|
Am J Cardiol
|
1995
|
0.75
|
|
21
|
Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study.
|
Am J Cardiol
|
1999
|
0.75
|
|
22
|
Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program.
|
Control Clin Trials
|
1999
|
0.75
|